MX353209B - Antagonistas d2, metodos de sintesis y metodos de uso. - Google Patents
Antagonistas d2, metodos de sintesis y metodos de uso.Info
- Publication number
- MX353209B MX353209B MX2014009737A MX2014009737A MX353209B MX 353209 B MX353209 B MX 353209B MX 2014009737 A MX2014009737 A MX 2014009737A MX 2014009737 A MX2014009737 A MX 2014009737A MX 353209 B MX353209 B MX 353209B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- antagonists
- synthesis
- compounds
- dopamine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan compuestos antagonistas D2 o D3 y composiciones farmacéuticas de la fórmula I (ver Fórmula) y sales farmacéuticamente aceptables de los mismos, o isómeros de los mismos, en donde R1, R2 y R3 son como se definen en la presente. La invención comprende además métodos para hacer los compuestos de la invención y métodos para el tratamiento de afecciones mediadas por el receptor de dopamina D2 o D3 de los compuestos de la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35609610P | 2010-06-18 | 2010-06-18 | |
| PCT/US2011/040983 WO2011160084A1 (en) | 2010-06-18 | 2011-06-17 | D2 antagonists, methods of synthesis and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX353209B true MX353209B (es) | 2018-01-08 |
Family
ID=44318118
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012014470A MX2012014470A (es) | 2010-06-18 | 2011-06-17 | Antagonistas d2, metodos de sintesis y metodos de uso. |
| MX2014009737A MX353209B (es) | 2010-06-18 | 2011-06-17 | Antagonistas d2, metodos de sintesis y metodos de uso. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012014470A MX2012014470A (es) | 2010-06-18 | 2011-06-17 | Antagonistas d2, metodos de sintesis y metodos de uso. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8691836B2 (es) |
| EP (2) | EP3138841A1 (es) |
| JP (1) | JP5860457B2 (es) |
| KR (1) | KR101601383B1 (es) |
| CN (1) | CN103052636B (es) |
| AU (1) | AU2011268073B2 (es) |
| CA (1) | CA2802188C (es) |
| CY (1) | CY1118541T1 (es) |
| DK (1) | DK2582701T3 (es) |
| ES (1) | ES2612471T3 (es) |
| HR (1) | HRP20170134T1 (es) |
| HU (1) | HUE031556T2 (es) |
| IL (3) | IL223515A (es) |
| LT (1) | LT2582701T (es) |
| MX (2) | MX2012014470A (es) |
| NZ (1) | NZ605431A (es) |
| PL (1) | PL2582701T3 (es) |
| PT (1) | PT2582701T (es) |
| RS (1) | RS55645B1 (es) |
| SI (1) | SI2582701T1 (es) |
| SM (1) | SMT201700064B (es) |
| WO (1) | WO2011160084A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2445343B1 (en) | 2009-06-25 | 2021-08-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| AU2016204605B2 (en) * | 2009-06-25 | 2017-11-23 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| DK2582701T3 (en) | 2010-06-18 | 2017-02-06 | Altos Therapeutics Llc | D2 ANTAGONISTS, SYNTHESIS PROCEDURES AND METHODS OF USE |
| ES2955693T3 (es) | 2012-12-24 | 2023-12-05 | Neurogastrx Inc | Métodos para el tratamiento de trastornos del tracto GI |
| US9844554B2 (en) | 2014-06-24 | 2017-12-19 | Neurogastrx, Inc. | Prodrugs of metopimazine |
| EP3233077A4 (en) | 2014-12-19 | 2018-08-08 | The Broad Institute Inc. | Dopamine d2 receptor ligands |
| EP3233799B1 (en) | 2014-12-19 | 2021-05-19 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
| JP7002335B2 (ja) * | 2015-07-03 | 2022-01-20 | エフ．ホフマン－ラ ロシュ アーゲー | Ｄｄｒ１阻害剤としてのトリアザ－スピロデカノン |
| WO2017137334A1 (en) | 2016-02-08 | 2017-08-17 | F. Hoffmann-La Roche Ag | Spiroindolinones as ddr1 inhibitors |
| GB201702250D0 (en) | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| US11202776B2 (en) * | 2017-05-12 | 2021-12-21 | Takeda Pharmaceutical Company Limited | Treatment of gastroparesis with triazaspiro[4.5]decanone |
| US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155670A (en) | 1962-06-22 | 1964-11-03 | Res Lab Dr C Janssen N V | 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes |
| BE633914A (es) * | 1962-06-22 | |||
| US3238216A (en) | 1963-06-20 | 1966-03-01 | Res Lab Dr C Janssen N V | Substituted 1, 3, 8-triaza-spiro (4, 5) decanes |
| US5182397A (en) | 1990-05-31 | 1993-01-26 | American Cyanamid Company | Aryloxyspiroalkylindolinone herbicides |
| US6277991B1 (en) * | 1998-05-18 | 2001-08-21 | Novo Nordisk A/S | 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
| WO1999059997A1 (en) | 1998-05-18 | 1999-11-25 | Novo Nordisk A/S | Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
| HUP0700269A2 (en) * | 2007-04-11 | 2009-04-28 | Richter Gedeon Nyrt | Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use |
| EP2185155B1 (en) * | 2007-08-03 | 2017-10-04 | Richter Gedeon Nyrt. | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands |
| DK2582701T3 (en) | 2010-06-18 | 2017-02-06 | Altos Therapeutics Llc | D2 ANTAGONISTS, SYNTHESIS PROCEDURES AND METHODS OF USE |
-
2011
- 2011-06-17 DK DK11728491.9T patent/DK2582701T3/en active
- 2011-06-17 ES ES11728491.9T patent/ES2612471T3/es active Active
- 2011-06-17 EP EP16192596.1A patent/EP3138841A1/en not_active Withdrawn
- 2011-06-17 LT LTEP11728491.9T patent/LT2582701T/lt unknown
- 2011-06-17 AU AU2011268073A patent/AU2011268073B2/en active Active
- 2011-06-17 PL PL11728491T patent/PL2582701T3/pl unknown
- 2011-06-17 KR KR1020137000599A patent/KR101601383B1/ko active IP Right Grant
- 2011-06-17 NZ NZ605431A patent/NZ605431A/en unknown
- 2011-06-17 CA CA2802188A patent/CA2802188C/en active Active
- 2011-06-17 SI SI201131089A patent/SI2582701T1/sl unknown
- 2011-06-17 JP JP2013515569A patent/JP5860457B2/ja active Active
- 2011-06-17 CN CN201180037718.2A patent/CN103052636B/zh active Active
- 2011-06-17 RS RS20170094A patent/RS55645B1/sr unknown
- 2011-06-17 PT PT117284919T patent/PT2582701T/pt unknown
- 2011-06-17 MX MX2012014470A patent/MX2012014470A/es active IP Right Grant
- 2011-06-17 HU HUE11728491A patent/HUE031556T2/en unknown
- 2011-06-17 WO PCT/US2011/040983 patent/WO2011160084A1/en active Application Filing
- 2011-06-17 US US13/163,592 patent/US8691836B2/en active Active
- 2011-06-17 MX MX2014009737A patent/MX353209B/es unknown
- 2011-06-17 EP EP11728491.9A patent/EP2582701B1/en active Active
-
2012
- 2012-12-09 IL IL223515A patent/IL223515A/en active IP Right Grant
-
2014
- 2014-02-19 US US14/184,615 patent/US9156840B2/en active Active
-
2017
- 2017-01-26 HR HRP20170134TT patent/HRP20170134T1/hr unknown
- 2017-01-27 SM SM201700064T patent/SMT201700064B/it unknown
- 2017-01-30 CY CY20171100133T patent/CY1118541T1/el unknown
- 2017-02-14 IL IL250606A patent/IL250606A0/en unknown
-
2018
- 2018-02-08 IL IL257429A patent/IL257429B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX353209B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
| TN2014000030A1 (en) | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators | |
| MX351305B (es) | Antagonistas del receptor de mineralocorticoides. | |
| MX363127B (es) | Derivados de benzotiofeno como inhibidores del receptor de estrogeno. | |
| AU2011234398A8 (en) | Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | |
| MX2011011156A (es) | COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2. | |
| MY169479A (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| MX2009004662A (es) | Compuestos de pirazolina como antagonistas receptores de mineralocorticoides. | |
| MY187718A (en) | Pharmaceutical formulations | |
| IN2012DN03182A (es) | ||
| TN2015000018A1 (en) | 5-ht3 receptor antagonists | |
| MX2015005735A (es) | Moduladores de dihidropirazol de receptor acoplado a la proteona g (gpr40). | |
| MX2015005720A (es) | Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40). | |
| MY160392A (en) | Triptolide prodrugs | |
| GEP20135806B (en) | Lactams as beta secretase inhibitors | |
| MX2015011536A (es) | Nuevos antagonistas de receptores trpa1 de sulfamidas. | |
| MY161749A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| MX2013006768A (es) | Moduladores de receptor de glucagon. | |
| EA201270556A1 (ru) | Конденсированные тиазоло и оксазолопиримидиноны | |
| ATE546448T1 (de) | Urotensin-ii-rezeptorantagonisten | |
| MX2010007929A (es) | Imidazolinilmetil aril sulfonamidas novedosas. | |
| MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
| MX337106B (es) | Antagonistas no competitivos de receptores nicotinicos. | |
| MX2014000855A (es) | Moduladores receptores de glucagon de quinolinilo. | |
| MX2010007928A (es) | Imidazolinilmetil aril sulfonamidas novedosas. |